Wolfe Research Rates Insmed (INSM) Peer Perform

Wolfe Research has downgraded its rating on Insmed Incorporated (NasdaqGS: INSM) to Peer Perform on October 12, 2026. This change comes as the company navigates challenges in its performance metrics, though no new price target was established in the report.

The downgrade reflects Wolfe Research's assessment of Insmed's recent developments. As of September 22, 2026, Insmed reported a trailing twelve-month revenue of approximately $1.14 billion, but it continues to face financial difficulties, including a net margin of -76.9%.

Other Institutional Activity in Insmed Incorporated

Several institutional investors have made notable changes to their positions in Insmed. FMR, LLC increased its holdings by 2,983,411 shares, bringing its total to about 16.1 million shares valued at approximately $1.55 billion. In contrast, Blackrock Inc. reduced its stake by 870,623 shares, ending with around 15.8 million shares worth about $1.52 billion. JPMorgan Chase & Co. cut its holdings significantly, selling 13,722,293 shares, which left it with about 10.4 million shares valued at roughly $1.00 billion. Vanguard Portfolio Management LLC saw a slight increase in its stake by 36,301 shares, totaling around 10.4 million shares worth about $1.00 billion.

Insmed Incorporated Stock Down 3.0%

Insmed's stock is currently trading around $96.2 as of October 16, 2026. This price is relevant as it indicates market sentiment following the downgrade by Wolfe Research. The stock has experienced volatility, and investors will be watching closely as the company approaches its next earnings report on October 29, 2026.

Recent Earnings

Insmed's revenue for the trailing twelve months stands at about $1.14 billion, reflecting a year-over-year growth of 296.1%. However, the company continues to report significant losses, with an EPS of -4.12. The upcoming earnings date on October 29, 2026, will be crucial for assessing its financial health moving forward.

Insider Buying and Selling at Insmed Incorporated

Recent insider activities include several sales. Martina Flammer, an officer, sold 27,173 shares, valued at about $3.49 million on August 6, 2026. Chief Operating Officer Roger Adsett sold 239,850 shares for around $31.96 million on August 10, 2026. Additionally, Director Melvin A. Sharoky sold 5,000 shares worth approximately $637,650 on August 17, 2026, and Director David R. Brennan sold 25,000 shares for about $3.10 million on September 9, 2026. These transactions occurred prior to the recent rating change.

Analysts Set New Price Targets

On October 12, 2026, Wolfe Research downgraded Insmed to Peer Perform. Meanwhile, HC Wainwright & Co. reiterated a Buy rating with a price target of $220. On August 10, 2026, JP Morgan maintained an Overweight rating with a target of $175, while Roth Capital reiterated a Buy rating with a target of $198 on September 15, 2026. Barclays also maintained its Overweight rating with a target of $207 on September 30, 2026. The consensus among analysts suggests a cautious outlook for Insmed as it navigates its operational challenges.

About Insmed Incorporated

Insmed Incorporated is a biotechnology company based in Bridgewater, NJ. It focuses on developing and commercializing therapies for patients with serious and rare diseases. The company’s key product, ARIKAYCE, treats refractory nontuberculous mycobacterial lung infections. Insmed is also in a phase 3 clinical trial for a treatment targeting mycobacterium avium complex lung disease.

Bottom Line

Investors should keep an eye on Insmed's upcoming earnings report on October 29, 2026, as it will provide further insight into the company's financial situation following the downgrade by Wolfe Research. The company's recent challenges and insider selling may influence market sentiment in the near term.